Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

High Dose Influenza Vaccination and Morbidity and Mortality in U.S. Nursing Homes

Trial Profile

High Dose Influenza Vaccination and Morbidity and Mortality in U.S. Nursing Homes

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Oct 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Oct 2018 Results of post hoc analysis evaluating whether a HD trivalent vaccine was associated with a reduced incidence of acute CV events (ACE) among nursing home (NH) residents, compared with a standard-dose trivalent vaccine presented at the IDWeek 2018
    • 08 Nov 2017 Planned End Date changed from 1 Dec 2016 to 1 May 2018.
    • 30 Oct 2016 Primary endpoint (Hospitalization rate) has been met, according to the results presented at the IDWeek 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top